Ashland, Massachusetts, USA, November 15, 2026
Medicept, a regulatory and quality consulting company serving the medical technology industry, has announced that its founder, F. David Rothkopf, will present an updated overview of U.S. Food and Drug Administration (FDA) inspection practices at MEDevice Silicon Valley 2026 in San Jose, California. The session, titled “This Is Not Your Father’s FDA,” is scheduled for November 18 and will address significant changes in how FDA investigators assess medical device manufacturers following the implementation of the Quality Management System Regulation (QMSR) on February 2, 2026. The regulatory transition has changed the inspection landscape for medical device companies, replacing the long-standing Quality System Inspection Technique (QSIT) approach with a more risk-focused inspection process. Under the updated approach, investigators examine how manufacturers identify, evaluate, control, and monitor risks throughout their quality management systems. Medicept aims to help medical device teams understand these changes and prepare their documentation, internal processes, and management systems for inspections. The presentation will also introduce a 30-point FDA Inspection Readiness Checklist, designed to help quality professionals assess their preparedness and identify areas requiring improvement. The announcement highlights the growing importance of regulatory compliance, risk management, and quality system effectiveness in the medical device industry.
FDA’s QMSR Changes Medical Device Inspection Practices
The FDA’s Quality Management System Regulation became effective on February 2, 2026, incorporating requirements aligned with the international medical device quality management standard ISO 13485:2016 while retaining additional FDA-specific requirements. With this transition, the agency retired its previous QSIT inspection approach, which had guided medical device inspections for decades. The revised inspection process places greater emphasis on evaluating whether a manufacturer’s quality management system effectively identifies and controls risks to patients and users. Rather than relying on the older inspection playbook, investigators can examine how risks are managed across different quality system processes and throughout the product lifecycle. Areas receiving attention include risk management, design and development controls, production processes, supplier management, corrective and preventive actions, and postmarket feedback. Medicept highlights that records such as management reviews, internal audits, and supplier audits are now important parts of inspection preparation. These documents can help investigators understand whether a manufacturer’s quality system is functioning effectively and whether identified issues are being addressed. For medical device manufacturers, the transition means that simply preparing documents for an inspection may not be sufficient. Companies need to demonstrate that their procedures are implemented, records are consistent, and risk-management activities are connected across the organization.
Medicept Introduces a 30-Point FDA Inspection Checklist
To support medical device manufacturers, Medicept has published an Inspection Readiness Checklist: FDA Inspections After QSIT, a 30-point self-assessment tool designed for quality and regulatory teams. The checklist begins with risk management and covers the six quality system areas, together with other FDA requirements addressed during inspections. It concludes with a scoring approach intended to help organizations understand their inspection readiness and identify potential gaps. One practical exercise asks teams to select a significant patient risk and trace it through the product lifecycle, from initial design inputs to postmarket feedback. The exercise challenges teams to locate the relevant records and demonstrate how the risk has been evaluated and controlled. Medicept recommends that organizations should be able to retrieve the supporting documentation efficiently, with the checklist using a target of less than 10 minutes for this exercise. This approach encourages companies to assess not only whether documents exist, but also whether information is accessible, consistent, and connected to actual quality processes. The checklist may be particularly useful for manufacturers whose inspection preparation procedures have not been updated since the introduction of QMSR. However, it is a company-developed readiness resource and does not replace FDA regulations, official guidance, or a formal compliance assessment.
Medicept Highlights Practical Preparation for Medical Device Teams
The upcoming session will be delivered by F. David Rothkopf, who has 35 years of experience in medical device development and regulatory strategy. According to Medicept, he has conducted more than 400 ISO 13485 and FDA-style audits and founded the company in 1996. His presentation will explain how inspections are conducted under the updated framework, which records investigators may request, why risk management is central to the process, and what manufacturers should prioritize when updating their inspection preparation. The session will take place on November 18, 2026, from 10:45 a.m. to 11:30 a.m. Pacific Standard Time, at the Design Studio Theater (805) during MEDevice Silicon Valley in San Jose. Medicept provides regulatory, quality, clinical, and commercialization services to medical device companies, including support through an in-house clinical research organization. The company’s focus is on helping organizations reduce compliance risks and coordinate quality and regulatory activities throughout product development and commercialization. Overall, the announcement highlights an important regulatory development for the medical device sector. Understanding and implementing QMSR requirements is essential for manufacturers seeking to maintain inspection readiness, strengthen quality management systems, and support patient safety.
Source: Medicept press release



